Palmitoylethanolamide

PreclinicalSmall molecule

TThe University of Texas Health Science Center, Houston

Palmitoylethanolamide is one of 4 small molecule programs targeting Chronic Low Back Pain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Low Back PainRecruiting

PalmitoylethanolamideNot yet recruiting

Chronic Low Back PainPreclinical

Recruiting

PalmitoylethanolamidePreclinical

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Chronic Low Back Pain

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Preclinical

1 2

Psilocybin

COMPASS Pathways

Phase 1

1 3

Palmitoylethanolamide

TThe University of Texas Health Science Center, Houston

Preclinical

1 4

CELZ-201-DDT

CCreative Medical Technology Holdings Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Chronic Low Back Pain

NCT07772141

Clinical

Trials by Indication[1]

Palmitoylethanolamide2 trials

Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Below Knee Fracture Fixation

Withdrawn·UUniversity of California, Irvine·Phase 2·NCT05317676

Palmitoylethanolamide vs Ibuprofen for Pain After ESWL

Not yet recruiting·—·N/A·NCT07316660·120 enrolled

Major Depression1 trial

PEA vs. Placebo for Major Depression

Unknown status·—·Phase 2·NCT06063369·100 enrolled

Craving1 trial

Endocannabinoids, Stress, Craving And Pain Effects Study

Completed·—·Phase 1·NCT05480072·12 enrolled

Chronic Low Back Pain1 trial

Palmitoylethanolamide Modulates Central Sensitisation and Neuroinflammation in Chronic Low Back Pain: A Randomized Controlled Trial With Neurophysiological and Biomarker Correlates

Recruiting·BBeni-Suef University·Preclinical·NCT07772141·106 enrolled

Bipolar Depression1 trial

A Randomized Controlled Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression

Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT06229977·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Palmitoylethanolamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Palmitoylethanolamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Palmitoylethanolamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center, Houston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe University of Texas Health Science Center, Houston

Palmitoylethanolamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Palmitoylethanolamide2 trials

Major Depression1 trial

Craving1 trial

Chronic Low Back Pain1 trial

Bipolar Depression1 trial

References

Drug Info

Quick Facts

Related News